Current status of D-penicillamine therapy in Japan.
A multicentric post-marketing surveillance study over 7 years including 5,124 patients is presented. According to clinical and laboratory data, the drug D-penicillamine was effective, with a tendency of loss of efficacy after therapy of 5 years or longer. Response was better in the early stage of the disease. Side effects were observed in 28.1% of the patients.
Kashiwazaki
S
S
School of Medicine Kitasato University, Kanagawa, Japan.
D000203:Activities of Daily Living; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007564:Japan; D007596:Joints / Q000187:drug effects; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing
D010396:Penicillamine